Down-modulation of TCR/CD3 surface complexes after HIV-1 infection is associated with differential expression of the viral regulatory genes

European Journal of Immunology

Volumn 31, Issue 4, 2001, Pages 969-979

  Willard Gallo, Karen E ^a   Furtado, Manohar ^b   Burny, Arséne ^a   Wolinsky, Steven M ^b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

CD3 ; HIV; TCR

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CD3 ANTIGEN; GAG PROTEIN; NEF PROTEIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; REV PROTEIN; SPLICED LEADER RNA; T LYMPHOCYTE RECEPTOR; TRANSACTIVATOR PROTEIN;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DENSITY; DOSE RESPONSE; DOWN REGULATION; GENE EXPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MODULATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURFACE PROPERTY; T LYMPHOCYTE SUBPOPULATION; TIME; TRANSCRIPTION REGULATION; VIRUS GENE;

ANTIGENS, CD3; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, NEF; GENE PRODUCTS, REV; GENE PRODUCTS, TAT; HIV CORE PROTEIN P24; HIV-1; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, VIRAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TIME FACTORS;

EID: 0035054394     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200104)31:4<969::AID-IMMU969>3.0.CO;2-2     Document Type: Article

References (55)

1. From TCR engagement to T cell activation: A kinetic view of T cell behavior
2. Atomic structure of an alphabeta T cell receptor (TCR) heterodimer in complex with an anti-TCR Fab fragment derived from a mitogenic antibody
3. Assembly of the TCR/CD3 complex: CD3 epsilon/delta and CD3 epsilon/gamma dimers associate indistinctly with both TCR alpha and TCR beta chains. Evidence for a double TCR heterodimer model
4. Preventing abnormalities in signal transduction of T cells in cancer: The promise of cytokine gene therapy
5. Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma
6. + mature human T cell populations and clones by human herpesvirus 6. Transcriptional down-regulation of CD3
7. + T cells
8. + T-cell line
9. Modulation of CD3-gamma gene expression after HIV type 1 infection of the WE17/10 T cell line is progressive and occurs in concert with decreased production of viral p24 antigen
10. Human immunodeficiency virus type 2 produces a defect in CD3-gamma gene transcripts similar to that observed for human immunodeficiency virus type 1
11. Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and down-modulate CD3 zeta, the signaling chain of the T-cell receptor complex
12. HIV infection-induced posttranslational modification of T cell signaling molecules associated with disease progression
13. + proliferative/cytotoxic T cell clone progresses in at least two distinct phases based on changes in function and phenotype of the infected cells
14. Human T cell leukemia virus type I prevents cell surface expression of the T cell receptor through down-regulation of the CD3-gamma, -delta, -epsilon, and -zeta genes
15. Discordant gene and surface expression of the T-cell receptor/CD3 complex in adult T-cell leukemia cells
16. T3 surface molecules on adult T cell leukemia cells are modulated in vivo
17. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition
18. + T helper lymphocytes in asymptomatic human immunodeficiency virus infection
19. Selective loss of T cell functions in different stages of HIV infection. Early loss of anti-CD3-induced T cell proliferation followed by decreased anti-CD3-induced cytotoxic T lymphocyte generation in AIDS-related complex and AIDS
20. Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection
21. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency
22. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort
23. Anti-human immunodeficiency virus type 1 activity of phosphorothioate analogs of oligodeoxynucleotides: Penetration and localization of oligodeoxynucleotides in HIV-1-infected MOLT-4 cells
24. Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates
25. Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro
26. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
27. Multiple modes of cellular activation and virus transmission in HIV infection: A role for chronically and latently infected cells in sustaining viral replication
28. + T-cell number decline in human immunodeficiency virus type 1-infected individuals
29. HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization
30. Separable functions of Nef disrupt two aspects of T cell receptor machinery: CD4 expression and CD3 signaling
31. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1
32. Human immunodeficiency virus Tat induces functional unresponsiveness in T cells
33. The Nef protein of HIV-1 associates with rafts and primes T cells for activation
34. Human immunodeficiency virus type 1 Nef binds directly to Lck and mitogen-activated protein kinase, inhibiting kinase activity
35. Nef and the Nef-associated kinase
36. The HIV nef protein associates with protein kinase C theta
37. Zeta chain of the T-cell receptor interacts with nef of simian immunodeficiency virus and human immunodeficiency virus type 2
38. The T-cell receptor zeta chain contains two homologous domains with which simian immunodeficiency virus Nef interacts and mediates down-modulation
39. Serine phosphorylation-independent down-regulation of cell-surface CD4 by nef
40. Down-regulation of cell surface CD4 by nef
41. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein
42. Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking
43. Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity
44. A dileucine motif in HIV-1 Nef is essential for sorting into clathrin- coated pits and for down-regulation of CD4
45. A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains
46. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients
47. Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat-activation
48. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription
49. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
50. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome
51. Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides
52. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms
53. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus
54. Analysis of alternatively spliced human immunodeficiency virus type-1 mRNA species, one of which encodes a novel tatenv fusion protein
55. Quantification of human immunodeficiency virus type 1 tat mRNA as a marker for assessing the efficacy of antiretroviral therapy